Ratings by Goldman Sachs (Richard Law)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/8/2026 | Rocket Pharmaceuticals | RCKT | Upgrade | Neutral (Sell) |
2.48 (2.20) |
-11.29% | Details | |
| 10/8/2026 | Rocket Pharmaceuticals | RCKT | Upgrade | Neutral (Sell) |
2.48 (2.48) |
0% | Details | |
| 9/22/2026 | Viking Therapeutic | VKTX | Maintain | Neutral (N/A) |
|
Details | ||
| 9/14/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2026 | Scribe Therapeutics Inc | SCTX | New Coverage | Early-Stage Biotech (N/A) |
20.73 (19.30) |
-6.9% | Details | |
| 8/12/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/10/2026 | Protagonist Therapeutics | PTGX | Upgrade | Buy (Neutral) |
146.18 (138.08) |
-5.54% | Details | |
| 5/26/2026 | Hemab Therapeutics Holdings | COAG | New Coverage | Buy (N/A) |
26.30 (35.34) |
34.37% | Details | |
| 5/12/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Neutral (N/A) |
|
Details | ||
| 5/7/2026 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2026 | Bicara Therapeutics Inc | BCAX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/18/2026 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Sell (N/A) |
|
Details | ||
| 3/2/2026 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/27/2026 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/11/2026 | Bicara Therapeutics Inc | BCAX | Downgrade | Neutral (Buy) |
14.97 (17.91) |
19.64% | Details | |
| 1/15/2026 | Moonlake Immunotherapeutics | MLTX | Downgrade | Sell (Neutral) |
17.10 (10.65) |
-37.72% | Details | |
| 1/13/2026 | Arcus Biosciences | RCUS | New Coverage | Buy (N/A) |
21.01 (19.10) |
-9.09% | Details | |
| 1/12/2026 | Crinetics | CRNX | Upgrade | Buy (Neutral) |
53.25 (84.95) |
59.53% | Details | |
| 12/18/2025 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 12/11/2025 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2025 | Nuvalent | NUVL | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2025 | Moonlake Immunotherapeutics | MLTX | Downgrade | Neutral (Buy) |
6.24 (17.10) |
174.04% | Details | |
| 9/29/2025 | Crinetics | CRNX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/20/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Sell (N/A) |
|
Details | ||
| 7/25/2025 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Neutral (N/A) |
14.91 (31.87) |
113.75% | Details | |
| 7/10/2025 | Crinetics | CRNX | New Coverage | Neutral (N/A) |
32.33 (53.25) |
64.71% | Details | |
| 7/1/2025 | Nuvalent | NUVL | New Coverage | Buy (N/A) |
79.68 (123.96) |
55.57% | Details | |
| 5/28/2025 | Rocket Pharmaceuticals | RCKT | Downgrade | Sell (Buy) |
2.33 (2.48) |
6.44% | Details | |
| 4/8/2025 | Viking Therapeutic | VKTX | New Coverage | Neutral (N/A) |
22.62 (26.38) |
16.62% | Details | |
| 3/10/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2025 | Silence Therapeutics | SLN | Maintain | Sell (N/A) |
|
Details | ||
| 3/3/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2025 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2025 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2025 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2025 | Moonlake Immunotherapeutics | MLTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/13/2025 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2025 | Silence Therapeutics | SLN | New Coverage | Sell (N/A) |
5.01 (19.67) |
292.61% | Details | |
| 1/17/2025 | Moonlake Immunotherapeutics | MLTX | Upgrade | Buy (Neutral) |
43.97 (6.24) |
-85.81% | Details | |
| 11/21/2024 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
43.49 (90.00) |
106.94% | Details | |
| 11/13/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2024 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2024 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2024 | Celldex Therapeutics | CLDX | Maintain | Neutral (N/A) |
|
Details | ||
| 9/30/2024 | Celldex Therapeutics | CLDX | New Coverage | Neutral (N/A) |
32.86 (29.37) |
-10.62% | Details | |
| 9/12/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 9/10/2024 | Olema Pharmaceuticals | OLMA | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 8/14/2024 | Mineralys Therapeutics, Inc. | MLYS | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2024 | Rocket Pharmaceuticals | RCKT | Maintain | Neutral (N/A) |
|
Details | ||
| 6/11/2024 | Viridian Therapeutic | VRDN | Maintain | Buy (N/A) |
|
Details | ||
| 6/6/2024 | Viridian Therapeutic | VRDN | New Coverage | Buy (N/A) |
12.34 (23.01) |
86.47% | Details | |
| 4/2/2024 | Moonlake Immunotherapeutics | MLTX | New Coverage | Neutral (N/A) |
50.23 (10.65) |
-78.8% | Details | |
| 4/2/2024 | Olema Pharmaceuticals | OLMA | New Coverage | Buy (N/A) |
11.32 (7.05) |
-37.72% | Details | |
| 4/2/2024 | Mineralys Therapeutics, Inc. | MLYS | New Coverage | Buy (N/A) |
12.91 (21.10) |
63.44% | Details | |
| 4/2/2024 | Rocket Pharmaceuticals | RCKT | New Coverage | Neutral (N/A) |
26.94 (2.33) |
-91.35% | Details |
